Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia



Status:Withdrawn
Conditions:Anemia
Therapuetic Areas:Hematology
Healthy:No
Age Range:65 - Any
Updated:4/21/2016
Start Date:December 2008
End Date:February 2011

Use our guide to learn which trials are right for you!

An Open-Label, Single-Arm Pilot Study of the Efficacy of Erythropoietin Alfa in Improving Peak Oxygen Consumption in Elderly Subjects With Unexplained Anemia

The primary objective of this study is to assess the ability of epoetin alfa to raise
hemoglobin (Hb) levels in elderly outpatients with unexplained anemia. The secondary
objectives of this study are to assess the ability of epoetin alfa to improve physical
function; cognitive function; and quality of life, and to assess the safety of epoetin alfa
in the study population.

Eligible subjects will be recruited out of the companion study "Anemia in the Elderly"
(NCT00640172), after active participation in that study is complete. Subjects will have had
a full hematologic evaluation, and unexplained anemia will have been previously defined.

Subjects will provide baseline physical function testing, including exercise testing on a
treadmill and testing how far patients can walk in 6 minutes (walk test), as well as quality
of life; activity level; and mental functioning.

Study visits will be weekly, and the dose level may be adjusted to achieve the target
hemoglobin level within 16 weeks. Once at target, the drug will be taken for a total of 12
additional weeks. The maximum time on the study drug could be 28 weeks, and the minimum time
be on the 14 weeks.

The walk tests and questionnaires will be repeated when the target hemoglobin level is
reached, and when treatment is completed. The tests about quality of life, activity level,
and mental functioning will be repeated at the end of treatment. Follow-up visits will be
every 4 weeks for 12 weeks to check for side effects.

INCLUSION CRITERIA:

- Aged ≥ 65

- Hb ≤ 11 g/dL

- Outpatient at either the VA Palo Alto Health Care Systems (VAPAHCS) or Stanford
Hospital and Clinics (SHC)

- Independently living in the community (ie, not institutionalized or living in a group
home)

- Ability to understand and the willingness to sign a written informed consent document

- Performance level ECOG 2 or better

- Diagnosis of unexplained anemia

EXCLUSION CRITERIA:

- Substance abuse or mental health or other problems that would affect compliance with
the protocol

- Predicted mortality based on co-morbidities of less than 3 months

- On any erythropoiesis-stimulating agent in the prior 3 months

- Known HIV; hepatitis B; or hepatitis C chronic infection

- Clinically significant and uncontrolled medical condition considered a high risk for
participation in an investigational study

- Serum albumin < 3 g/dL

- Use of an investigational medication or participation in an investigational study
within 4 weeks prior to enrollment in the trial

- Liver disease as defined as total bilirubin ≥ 2 g/dL or AST/ALT ≥ 2 times the upper
limit of normal

- Allergy to recombinant human erythropoietin

- Estimated glomerular filtration rate by Modification of Diet in Renal Disease (MDRD)
equation of < 30 mL/min/1.73 m2 or dialysis

- History of proximal deep venous thrombosis or pulmonary embolism within the past 12
months

- Known contraindication to exercise testing
We found this trial at
3
sites
291 Campus Dr
Stanford, California 94305
(650) 725-3900
Stanford University School of Medicine Vast in both its physical scale and its impact on...
?
mi
from
Stanford, CA
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Palo Alto, California 94304
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials